Autres langues Marinus Pharmaceuticals, Inc.

Actions

MRNS

US56854Q2003

Temps réel estimé Cboe BZX Autres places de cotation 19:28:20 01/05/2024			Varia. 5j.	Varia. 1 janv.
1,445 ^USD	+2,48 %		+0,66 %	-86,67 %

17/04	MARINUS PHARMACEUTICALS, INC. : Truist Securities reste à l'achat	ZM
16/04	MARINUS PHARMACEUTICALS, INC. : Baird n'est plus acheteur	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024	14:10
North American Morning Briefing : Powell Comments, -2-	16/04
Sector Update: Health Care Stocks Softer Late Afternoon	15/04
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone	15/04
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results	15/04
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	15/04
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	05/04
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	28/03
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review	27/03
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to S&P Pharmaceuticals Select Industry Index	18/03
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency	07/03
UK Approves Marinus Pharmaceuticals' Ztalmy for Rare Genetic Disorder	07/03
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	06/03
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket	06/03
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours	05/03
Marinus Pharmaceuticals: Q4 Earnings Snapshot	05/03
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Marinus Pharmaceuticals : Corporate Overview Slide Deck	05/03
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M	05/03
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Marinus Pharmaceuticals, Inc.

Actions

MRNS

US56854Q2003

Autres langues

Filtres